---
title: "ZYME.US (ZYME.US) — 相关新闻"
type: "Symbol"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/quote/ZYME.US/news.md"
symbol: "ZYME.US"
name: "ZYME.US"
parent: "https://longbridge.com/zh-CN/quote/ZYME.US.md"
datetime: "2026-03-14T09:33:27.131Z"
locales:
  - [en](https://longbridge.com/en/quote/ZYME.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/ZYME.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/ZYME.US/news.md)
---

> 支持的语言: [English](https://longbridge.com/en/quote/ZYME.US/news.md) | [繁體中文](https://longbridge.com/zh-HK/quote/ZYME.US/news.md)


# ZYME.US (ZYME.US) — 相关新闻

### [12 Health Care Stocks Moving In Monday's Pre-Market Session](https://longbridge.com/zh-CN/news/278390342.md)
*2026-03-09T12:05:42.000Z*
> In Monday's pre-market session, several health care stocks saw significant movement. Relmada Therapeutics (RLMD) surged 

### [BETA Technologies, Starfighters Space And Other Big Stocks Moving Lower In Monday's Pre-Market Session](https://longbridge.com/zh-CN/news/278388432.md)
*2026-03-09T12:02:12.000Z*
> U.S. stock futures are down, with the Dow futures falling over 1%. BETA Technologies (NYSE: BETA) shares dropped 3.1% in

### [Why Lisata Therapeutics Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket](https://longbridge.com/zh-CN/news/278368177.md)
*2026-03-09T08:54:10.000Z*
> Lisata Therapeutics shares surged 20.3% to $5.03 in pre-market trading after agreeing to be taken private by Kuva Labs f

### [Zymeworks clears technical benchmark, hitting 90-plus RS rating](https://longbridge.com/zh-CN/news/277808382.md)
*2026-03-04T16:09:16.000Z*
> Zymeworks sees its Relative Strength Rating move into the elite 90-plus level.

### [Zymeworks (NASDAQ:ZYME) Price Target Raised to $47.00](https://longbridge.com/zh-CN/news/277663944.md)
*2026-03-03T18:11:39.000Z*
> Stifel Nicolaus raised Zymeworks' price target from $40.00 to $47.00, maintaining a "buy" rating. This suggests a potent

### [Forecasting The Future: 4 Analyst Projections For Zymeworks](https://longbridge.com/zh-CN/news/277662888.md)
*2026-03-03T18:01:13.000Z*
> Analysts' ratings for Zymeworks (NASDAQ:ZYME) show a mix of bullish to bearish sentiments over the last quarter. The ave

### [Zymeworks and Royalty Pharma Enter into $250 Million Royalty-Backed Note Financing | ZYME Stock News](https://longbridge.com/zh-CN/news/277451874.md)
*2026-03-02T03:01:00.000Z*
> Zymeworks has secured $250 million in non-dilutive capital through a royalty-backed note financing from Royalty Pharma. 

### [Zymeworks and Royalty Pharma secure $250m financing through royalty-backed note; repayments from 30% of tiered royalties on Ziihera®.](https://longbridge.com/zh-CN/news/277453940.md)
*2026-03-02T11:03:08.000Z*
> Today, Zymeworks Inc. (Nasdaq: ZYME) and Royalty Pharma plc (Nasdaq: RPRX) disclosed a financial deal in Vancouver and N